Stock Ticker

  • Loading stock data...

OncoSec Medical Gains on Optimistic Cancer Immunotherapy Update (ONCS)

OncoSec Medical’s (OTC: ONCS) CEO and President, Punit Dhillon, revealed in an interview published in Seeking Alpha that not only will the company provide the subset data from the melanoma and Merkel cell program before the end of 2012, but will also provide an update on deals pertaining to the NeoPulse program. The CEO also expressed […]

Emisphere Technologies Tanks on Payment Default (EMIS)

The failure to pay $30.517 million in principal and interest for the 11% senior secured convertible notes and $600,000 in principal for promissory notes has placed Emisphere Technologies (OTC: EMIS) on the verge of facing a foreclosure of substantially all of its assets by the creditor MHR Fund Management (MHR). Reacting to the news, the […]

Discontinuation of Suboxone Tablet Supply Boosts Prospects of Titan Pharmaceuticals (TTNP)

Reckitt Benckiser’s decision to discontinue the supply of Suboxone tablets could not have come at a better time for Titan Pharmaceuticals (OTC: TTNP). Titan is well positioned to bring out new drug applications for buprenorphine-based products for treatment of opioid addiction and dependence. Reckitt Benckiser’s voluntary withdrawal decision was based on the analysis of data […]

TherapeuticsMD Paddles Like a Duck Today (TXMD)

Another day and another company announces the offering of more common shares to bolster its finances. Last night after the markets closed, TherapeuticsMD (OTC: TXMD) let the word out that it had entered into an agreement for the private placement of common stock. The deal calls for TherapeuticsMD to sell 3,953,489 shares of common stock […]

TherapeuticsMD Enters $8.5 Million Private Placement Agreement (TXMD)

Specialty pharmaceutical company TherapeuticsMD (OTC: TXMD) has just made a positive announcement for shareholders and investors by revealing information about a Securities Purchase Agreement that it has signed with accredited investors. As per the terms of the agreement, TherapeuticsMD has agreed to enter 3,953,489 of its common stock shares in a private placement at a […]

Public Offering Gives Little Inspiration to Traders (NSPR)

Nothing motivates sellers in a stock quicker than a company hinting of or executing a public offering for additional shares of common stock. For many small cap companies, their ability to raise funds often depends on the public offering route. InspireMD (OTC: NSPR) announced this morning it had filed a registration statement with the SEC for a […]

Peregrine Pharmaceuticals Rebounds After Bad Trial Data

A few days ago, Peregrine Pharmaceuticals (PPHM) was a $500 million company. Yesterday, it fell below $80 million. Today, it is worth $177 million. Needless to say, investors are feeling the whiplash, and they certainly have a fair share of questions. Yesterday, Peregrine Pharma dropped sharply in pre-market trading due to serious problems discovered in its bavituximab trial data. The company […]

Ready, Set, Go…Cellceutix Prepares for Clinical Trials (CTIX)

In a news release this morning, Cellceutix (OTC: CTIX) updated shareholders on the progress of clinical trials scheduled for its anti-cancer drug, Kevetrin. The trials will be conducted at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Earlier in the month, the company had amended the clinical protocol for the drug, which the Institutional Review […]

NanoViricides Gains on Oral FluCide’s Effectiveness Over Tamiflu (NNVC)

The nano-biopharmaceutical company NanoViricides (OTC: NNVC) reported that animal survival showed significant improvement when treated with oral FluCide, an anti-influenza drug candidate. The company also claimed that based on the survival time, its drug is functionally more effective than Roche’s (NASDAQ: ROCM) Tamiflu, when tested in animals administered with a lethal dose of the H3N2 […]

Cellceutix Announces Commencement of Clinical Trials for Anti-Cancer Drug Kevetrin (CTIX)

Cellceutix (OTC: CTIX) has just made a positive announcement for its shareholders who will be happy to know that the company is all set to start clinical trials for its novel anti-cancer drug Kevetrin. The announcement was made earlier in the day, and the clinical trials will be undertaken at the Harvard Cancer Center’s Dana […]

Galtech Semiconductor Spikes on Contract PR, Questions Linger

Galtech Semiconductor Materials (OTC: GTSM) spiked today after a PRNewsWire.com press release stated that the company had received a $5.7 million contract. At precisely 2:11pm ET, Galtech announced that it had “received an advanced architectural, advanced technology, contract from a private firm” [sic]. Shares of the firm had been trading near their historical price levels of […]

Neuralstem Retraces Gains After ALS Surgery Success

Neuralstem (AMEX: CUR) has gained considerable ground from its capital offering at $0.40 last month, but shares have nevertheless backed off considerably from their highs of $1.96. As of Friday’s close, Neuralstem was trading at $1.26, valuing the company at a market capitalization of $68 million. After announcing a special placement at $0.40, Neuralstem completed […]

Sign Up To Get Our Latest Stocks Alerts